From sympathetic overdrive phenotype to malignant transformation: 3PM-guided protection against health-to-disease transition and disease progression improving individual outcomes in primary and secondary care
Authors:
- Peter KubatkaPKPeter Kubatka
- Andrea KapinovaAKAndrea Kapinova
- Bianka BojkovaBBBianka Bojkova
- Vennila JosephVJVennila Joseph
- Slavomir HornakSHSlavomir Hornak
- Karol KajoKKKarol Kajo
- Dietrich BüsselbergDietrich Büsselberg
- Karel SmejkalKarel Smejkal
- Vadim GoncharenkoVGVadim Goncharenko
- Barbara MrazovaBMBarbara Mrazova
- Miroslava FövényesMFMiroslava Fövényes
- Rostyslav BubnovRBRostyslav Bubnov
Open Access
- 29 April 2026
- journal article
- research article
- Published by Springer Nature in EPMA Journal
- Vol. 17 (2) , 205-232
Abstract
Chronic sympathoexcitation (sympathetic overdrive syndrome) is defined as the sustained dominance of sympathetic over parasympathetic tone, measurable at the organ, vascular, and neural levels, and differs fundamentally from brief, adaptive “fight-or-flight” responses. Persistent vasoconstrictor drive perturbs cellular metabolism and reshapes host–tumor interfaces. Although this state is well characterized in cardiometabolic medicine, its oncologic implications remain comparatively underexplored, despite converging evidence that adrenergic inputs modulate tumor and stromal behavior. One of the main reasons for presenting this conceptual innovation study is that the sympathetic overdrive phenotype (SOP) carriers, by far, are not rare in the population. Robust statistics towards SOP incidence and prevalence are still missing, despite the urgency of plausible healthcare solutions. Currently, the best described SOP-relevant subpopulation are the Flammer Syndrome phenotype (FSP) carriers who, for instance, are highly prevalent in the academic career-making professional groups. Certain genetic predispositions play a role, however, the key pathways involved into the health-to-disease transition are epigenetically regulated and, to a large extent, represent systemic modifiable phenotype-associated risk factors which are, therefore, a promising target for holistic proactive medical approaches with a high potential to save lives and financial resources. Graphical Abstract The alternative text for this image may have been generated using AI.Keywords
Funding Information
- Rheinische Friedrich-Wilhelms-Universität Bonn
This publication has 263 references indexed in Scilit:
- Treatment of obstructive sleep apnea with CPAP improves daytime sleepiness and fatigue in cancer patientsCancer Medicine, 2024
- Relative Dose Intensity of Chemotherapy and Survival in Patients with Advanced Stage Solid Tumor Cancer: A Systematic Review and Meta-AnalysisThe Oncologist, 2021
- Perioperative COX2 and β‐adrenergic blockade improves biomarkers of tumor metastasis, immunity, and inflammation in colorectal cancer: A randomized controlled trialCancer, 2020
- Increased Resting Heart Rate and Prognosis in Treatment-Naïve Unselected Cancer Patients: Results from a Prospective Observational StudyEuropean Journal of Heart Failure, 2020
- Recent advances in the biology of tumour hypoxia with relevance to diagnostic practice and tissue‐based researchThe Journal of Pathology, 2020
- Chronic psychological stress promotes lung metastatic colonization of circulating breast cancer cells by decorating a pre‐metastatic niche through activating β‐adrenergic signalingThe Journal of Pathology, 2017
- Clinical impact of selective and nonselective beta‐blockers on survival in patients with ovarian cancerCancer, 2015
- Selective β2‐AR Blockage Suppresses Colorectal Cancer Growth Through Regulation of EGFR‐Akt/ERK1/2 Signaling, G1‐Phase Arrest, and ApoptosisJournal of Cellular Physiology, 2015
- Phase 3, randomized, placebo‐controlled study of zibotentan (ZD4054) in patients with castration‐resistant prostate cancer metastatic to boneCancer, 2012
- Expression patterns of endothelin‐1 and its receptors in colorectal cancerJournal of Surgical Oncology, 2011